Caribou Biosciences receives FDA IND clearance for CB-010 in lupus; GALLOP Ph1 trial expected by YE 2024

Caribou Biosciences, Inc.

FDA cleared IND for CB-010 (allogeneic anti-CD19 CAR-T) to treat lupus nephritis and extrarenal lupus.
Phase 1 GALLOP trial expected to initiate by year-end 2024; evaluates safety of single infusion with partial HLA matching.
CB-010 clinical development expanded from oncology to autoimmune diseases; driven by encouraging initial ANTLER trial data in r/r B-NHL.
Caribou reports $372.4M cash as of Dec 31, 2023, expected to fund operations into Q1 2026.
Initial dose expansion data from ANTLER Phase 1 trial for 2L LBCL to be presented at a medical congress in Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.